[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0508574A - métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides - Google Patents

métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides

Info

Publication number
BRPI0508574A
BRPI0508574A BRPI0508574-8A BRPI0508574A BRPI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A
Authority
BR
Brazil
Prior art keywords
methods
serum
glutamate receptors
glucocorticoid
neuropsychiatric disorders
Prior art date
Application number
BRPI0508574-8A
Other languages
English (en)
Inventor
Florian Lang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0508574A publication Critical patent/BRPI0508574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

MéTODOS PARA MODULAR RECEPTORES DE GLUTAMATO PARA TRATAR DISTúRBIOS NEUROPSIQUIáTRICOS COMPREENDENDO O USO DE MODULADORES DE QUINASES SéRICAS E INDUZIDAS POR GLICOCORTICóIDES.A presente invenção refere-se a modulação da atividade de quinases séricas e induzidas por glicocorticóide para restaurar a atividade do receptor de glutamanto.Também descritos são métodos e compostos úteis para a detecção e tratamento de distúrbios
BRPI0508574-8A 2004-03-11 2005-02-08 métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides BRPI0508574A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005761 2004-03-11
PCT/EP2005/001245 WO2005094829A1 (en) 2004-03-11 2005-02-08 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases

Publications (1)

Publication Number Publication Date
BRPI0508574A true BRPI0508574A (pt) 2007-08-14

Family

ID=34960898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508574-8A BRPI0508574A (pt) 2004-03-11 2005-02-08 métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides

Country Status (12)

Country Link
US (1) US20070191326A1 (pt)
EP (1) EP1732563A1 (pt)
JP (1) JP2007529423A (pt)
KR (1) KR20070015148A (pt)
CN (1) CN1929846A (pt)
AU (1) AU2005229496A1 (pt)
BR (1) BRPI0508574A (pt)
CA (1) CA2559136A1 (pt)
MX (1) MXPA06010268A (pt)
RU (1) RU2006135654A (pt)
WO (1) WO2005094829A1 (pt)
ZA (1) ZA200608447B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531020A (ja) * 2006-01-31 2009-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルココルチコイド誘導胃酸分泌を阻害するための方法
WO2007100888A2 (en) 2006-03-02 2007-09-07 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
EP2015638A4 (en) * 2006-04-28 2010-09-29 Redpoint Bio Corp TRIARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS TASTE INHIBITORS
CN102143752B (zh) 2008-08-05 2014-12-10 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
RU2580654C1 (ru) * 2015-04-16 2016-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения эпилепсий с продолженной спайк-волновой активностью во сне
WO2018156401A1 (en) * 2017-02-24 2018-08-30 Indiana University Research And Technology Corporation Methods of inhibiting serum glucocorticoid induced kinase 1 (sgk1) as a treatment for salt and water balance diseases
KR102331240B1 (ko) * 2019-03-21 2021-11-29 재단법인대구경북과학기술원 Sgk3 유전자를 이용한 뇌신경계 질환의 진단 및 치료
KR20210008193A (ko) * 2019-07-10 2021-01-21 한양대학교 산학협력단 염증성 신경 질환의 치료제로서 Sgk1 저해제의 용도
KR102645546B1 (ko) * 2021-06-10 2024-03-08 전남대학교 산학협력단 간성뇌증에 의해 유발되는 신경학적 또는 정신학적 장애 관련 질환 진단용 마커 및 이를 이용한 간성뇌증에 의해 유발되는 신경학적 또는 정신학적 장애 관련 질환 진단에 필요한 정보를 제공하는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
DE69937159T2 (de) * 1998-12-14 2008-06-26 University Of Dundee, Dundee Verfahren zur Aktivierung von SGK durch Phosphorylierung.
US20050064501A1 (en) * 1999-04-20 2005-03-24 Prof. Dr. Med. F. Lang Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone

Also Published As

Publication number Publication date
KR20070015148A (ko) 2007-02-01
ZA200608447B (en) 2008-07-30
AU2005229496A1 (en) 2005-10-13
CN1929846A (zh) 2007-03-14
CA2559136A1 (en) 2005-10-13
US20070191326A1 (en) 2007-08-16
WO2005094829A1 (en) 2005-10-13
EP1732563A1 (en) 2006-12-20
RU2006135654A (ru) 2008-09-10
MXPA06010268A (es) 2007-04-23
JP2007529423A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
BRPI0511072A (pt) derivados de alquinila como moduladores dos receptores de glutamato metabotróbico
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
BRPI0511616A (pt) compostos
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
BRPI0513899A (pt) moduladores de cinase heterocìclica de anel fundido
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
CY1110828T1 (el) Τροποποιημενοι πυριμιδινικοι ρυθμιστες του γλυκοκορτικοειδους υποδοχεα
BRPI0508574A (pt) métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
CL2007002595A1 (es) Compuestos derivados de n-(1-hetaril-piperidin-4-il)-(het)arilamida, moduladores del receptor ep2; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de la fertilidad, trastornos menstruale
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
PL1931335T3 (pl) Modulatory heksahydrocyklooktylopirazolokannabinoidowe
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.